Global Rank
#806
Country Rank
#68
Market Cap
30.73 B
Price
17.14
Change (%)
0.51%
Volume
5.97 M
Astellas Pharma's latest marketcap:
30.73 B
As of 11/17/2026, Astellas Pharma's market capitalization has reached $30.73 B. According to our data, Astellas Pharma is the 806th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 30.73 B |
| Revenue (ttm) | 14.94 B |
| Net Income (ttm) | 2.42 B |
| Shares Out | 1.79 B |
| EPS (ttm) | 1.35 |
| Forward PE | 12.87 |
| Ex-Dividend Date | 03/30/2027 |
| Earnings Date | 11/04/2026 |
Market Cap Chart
Data Updated: 11/17/2026
Astellas Pharma's yearly market capitalization.
Astellas Pharma has seen its market value grow from ¥3.72 T to ¥4.9 T since 2014, representing a total increase of 31.47% and an annual compound growth rate (CAGR) of 2.33%.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 11/17/2026 | ¥4.9 T | $30.73 B | 31.6% | 806 |
| 12/30/2025 | ¥3.75 T | $24.12 B | 36.48% | 1131 |
| 12/30/2024 | ¥2.75 T | $17.47 B | -9.13% | 1058 |
| 12/29/2023 | ¥3.02 T | $21.43 B | -17.34% | 838 |
| 12/30/2022 | ¥3.66 T | $27.87 B | 5.52% | 606 |
| 12/30/2021 | ¥3.47 T | $30.12 B | 17.06% | 679 |
| 12/30/2020 | ¥2.96 T | $28.66 B | -15.46% | 622 |
| 12/30/2019 | ¥3.5 T | $32.25 B | 30.09% | 439 |
| 12/28/2018 | ¥2.69 T | $24.55 B | -7.69% | 462 |
| 12/29/2017 | ¥2.92 T | $25.87 B | -14.25% | 496 |
Company Profile
Astellas Pharma Inc. Overview
Astellas Pharma Inc. is a leading pharmaceutical company specializing in the manufacturing, marketing, and import/export of pharmaceuticals in Japan and internationally.
Key Products and Treatments
- XTANDI – A treatment for prostate cancer.
- XOSPATA – For patients with relapsed or refractory acute myeloid leukemia (FLT3 mutation).
- PADCEV – A treatment for metastatic urothelial cancer.
- Evrenzo – Targets anemia associated with chronic kidney disease.
- Betanis/Myrabetriq/BETMIGA – For overactive bladder.
- Prograf & Advagraf/Graceptor/ASTAGRAF XL – Immunosuppressants.
Strategic Collaborations
- Research partnership with Vivtex Corporation to evaluate GI-ORIS screening and formulation technology.
- Agreement with Roche Diabetes Care Japan to develop diabetes self-management solutions.
Company Background
Originally founded in 1923 as Yamanouchi Pharmaceutical Co. Ltd., the company rebranded as Astellas Pharma Inc. in April 2005. It is headquartered in Tokyo, Japan.
Frequently Asked Questions
-
What is Astellas Pharma's (TYO-4503) current market cap?As of 11/17/2026, Astellas Pharma (including the parent company, if applicable) has an estimated market capitalization of $30.73 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Astellas Pharma (TYO-4503) rank globally by market cap?Astellas Pharma global market capitalization ranking is approximately 806 as of 11/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.